Posaconazole Dr. Reddy's Dosage/Direction for Use

Non-Interchangeability between POSACONAZOLE DR. REDDY'S Modified Release Tablets and Posaconazole Oral Suspension: POSACONAZOLE DR. REDDY'S Modified Release Tablets and oral suspension are not to be used interchangeably due to the differences in the dosing of each formulation. Therefore, follow the specific dosage recommendations for each of the formulations.
POSACONAZOLE DR. REDDY'S Modified Release Tablets may be taken without regard to food intake.
POSACONAZOLE DR. REDDY'S Modified Release Tablets are intended for oral administration only.
POSACONAZOLE DR. REDDY'S Modified Release Tablets should be swallowed whole, and not be divided, crushed, or chewed.
Important Administration Instructions for POSACONAZOLE DR. REDDY'S Modified Release Tablets and Posaconazole Oral Suspension: The prescriber should follow the specific dosing instructions for each formulation. The modified release tablet and oral suspension are not to be used interchangeably due to the differences in the dosing of each formulation.
Co-administration of drugs that can decrease the plasma concentrations of posaconazole should generally be avoided unless the benefit outweighs the risk. If such drugs are necessary, patients should be monitored closely for breakthrough fungal infections (see Interactions).
Refractory Invasive Fungal Infections (IFI)/Intolerant Patients with IFI: Loading dose of 300 mg (three 100 mg tablets) twice a day on the first day, then 300 mg (three 100 mg tablets) once a day thereafter. Duration of therapy should be based on the severity of the underlying disease, recovery from immunosuppression, and clinical response.
Prophylaxis of Invasive Fungal Infections: Loading dose of 300 mg (three 100 mg tablets) twice a day on the first day, then 300 mg (three 100 mg tablets) once a day thereafter. Duration of therapy is based on recovery from neutropenia or immunosuppression. For patients with acute myelogenous leukemia or myelodysplastic syndromes, prophylaxis with POSACONAZOLE DR. REDDY'S should start several days before the anticipated onset of neutropenia and continue for 7 days after the neutrophil count rises above 500 cells per mm³.
Use in renal impairment: No dose adjustment is required for renal dysfunction and posaconazole is not significantly renally eliminated, an effect of severe renal insufficiency on the pharmacokinetics of posaconazole is not expected and no dose adjustment is recommended.
Due to variability in exposure, patients with severe renal impairment should be monitored closely for breakthrough fungal infections.
Use in hepatic impairment: There are limited pharmacokinetic data in patients with hepatic insufficiency; therefore, no recommendation for dose adjustment can be made. In the small number of subjects studied who had hepatic insufficiency, there was an increase in half-life with a decrease in hepatic function.
Use in pediatrics: Safety and efficacy in children and adolescents below the age of 18 years have not been established. Therefore, posaconazole is not recommended for use in patients below 18 years of age.
Use in the Elderly: No dosage adjustment is recommended for elderly patients.